Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Phase 2

Terminated

• Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Interventions: Drug: NewGam 10%; Drug: Placebo

• Registration Number: NCT01225276
• Lead Sponsor: Octapharma

Brief Summary

NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV). This study will evaluate the safety and efficacy of three different dosages of NewGam 10% in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Detailed Description

This is a Phase 2/3 study that will take place in 2 stages. The primary objective of Stage 1 (Phase 2 dose-finding part)is to determine and select one dosage from three NewGam maintenance dosage arms in comparison with a placebo arm, based on the percentage of responders (response defined as a decrease, meaning improvement, in the adjusted INCAT disability score by at least 1 point). The selected NewGam dosage and placebo will be employed and compared in Stage 2.

The primary objective of Stage 2 (Phase 3 confirmatory part) is to demonstrate superiority of the maintenance dosage regimen selected at study Stage 1 over placebo in patients with CIDP as assessed by the percentage of responders.

The secondary objective is to evaluate the safety (measured by number of adverse events)and efficacy of NewGam administration in patients with CIDP compared to baseline.

Study Timeline

• Study First Submitted: 2010-10-06
• Study First Submitted QC: 2010-10-19
• Study First Posted: 2010-10-20
• Study Start: 2011-10
• Primary Completion: 2012-10
• Study Completion: 2012-10
• Disposition First Submitted: 2015-06-05
• Disposition First Submitted QC: 2015-10-16
• Disposition First Posted: 2015-11-06
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-20
• Last Update Posted: 2017-02-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Patients diagnosed as having CIDP based on fulfilment of clinical criteria of the INCAT Group and the definite electrophysiological criteria for CIDP ; patients with MADSAM or pure motor CIDP will be included provided they fulfil these criteria
• Worsening of disability and objective increase in weakness or sensory deficit during the 6 months prior to screening
• >=18 years of age

Exclusion Criteria

• Unifocal forms of CIDP
• Pure sensory CIDP
• MMN with conduction block
• Treatment of CIDP with immunoglobulins (intravenous or subcutaneous) at any time prior to study entry
• Steroids of any type equivalent to prednisolone or prednisone > 10 mg/day or equivalent plasma exchange (PE) during the last 3 months prior to baseline visit
• Treatment with cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil, interferon or other immunosuppressive or immunomodulatory drugs during the three months prior to baseline visit
• Clinical evidence of peripheral neuropathy from another
• Known diabetes mellitus
• Other serious medical condition complicating assessment or treatment
• Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever
• Known IgA deficiency with antibodies to IgA
• History of hypersensitivity, anaphylaxis or severe systemic response to immunoglobulin, blood or plasma derived products, or any component of NewGam
• Known blood hyperviscosity

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dosage Arm 1	NewGam 10%	NewGam 10% 0.4 g/kg
Dosage Arm 4	Placebo	Placebo 0.9% Saline
Dosage Arm 2	NewGam 10%	NewGam 10% 1.0 g/kg
Dosage Arm 3	NewGam 10%	NewGam 10% 2.0 g/kg

Primary Outcome Measures

Name	Time	Method
Adjusted INCAT disability score	Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)

Secondary Outcome Measures

Name	Time	Method
Vital Signs	During each infusion - Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)
Grip Strength	Visit 9 & 13
Nerve Conduction Studies	Visti 9 & 13
Motor Impairment Assessment utlizing the Expanded MRC Sum Score	Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)	Expanded 'Medical Research Council sum score' will be measured as improvement in MRC units .